FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019416118> ?p ?o ?g. }

• W2019416118 endingPage "107" @default.
• W2019416118 startingPage "101" @default.
• W2019416118 abstract "<b><i>Objective:</i></b> S-1 is effective in sequential combination with irinotecan (IRIS) in treating metastatic colorectal cancer. We conducted a randomized phase II trial of modified leucovorin, fluorouracil and irinotecan (mFOLFIRI) + bevacizumab and sequential IRIS + bevacizumab as first- or second-line therapies. <b><i>Methods:</i></b> Sixty metastatic colorectal cancer patients were randomly assigned to receive mFOLFIRI + bevacizumab or sequential IRIS + bevacizumab (7.5 mg/kg of bevacizumab and 150 mg/m² of irinitecan, and 80 mg/m²/day of S-1 orally from day 3 until day 16 as a 3-week course). The primary endpoint was the safety of each method until week 12, with the secondary endpoint being the comparison of the safety and efficacy of the two methods. <b><i>Results:</i></b> The safety of the two treatments was comparable, except that G3 anorexia and diarrhoea were less frequent with sequential IRIS + bevacizumab. The overall response rate was 62% [95% confidence interval (CI) 40.1–79.8] versus 72% (95% CI 50.6–86.2), and progression-free survival was 324 days (95% CI 247–475) versus 345 days (95% CI 312–594) with mFOLFIRI + bevacizumab versus IRIS + bevacizumab, respectively. <b><i>Conclusion:</i></b> Sequential IRIS + bevacizumab is a safe and effective method of systemic chemotherapy against metastatic colorectal cancer and is compatible with mFOLFIRI + bevacizumab." @default.
• W2019416118 created "2016-06-24" @default.
• W2019416118 creator A5000941260 @default.
• W2019416118 creator A5000947818 @default.
• W2019416118 creator A5013149772 @default.
• W2019416118 creator A5015096398 @default.
• W2019416118 creator A5023481395 @default.
• W2019416118 creator A5040998619 @default.
• W2019416118 creator A5044498041 @default.
• W2019416118 creator A5047792722 @default.
• W2019416118 creator A5047801629 @default.
• W2019416118 creator A5052439214 @default.
• W2019416118 creator A5054084673 @default.
• W2019416118 creator A5061614047 @default.
• W2019416118 creator A5064504927 @default.
• W2019416118 creator A5069433827 @default.
• W2019416118 creator A5071947905 @default.
• W2019416118 creator A5073041790 @default.
• W2019416118 date "2012-01-01" @default.
• W2019416118 modified "2023-09-27" @default.
• W2019416118 title "Safety Verification Trials of mFOLFIRI and Sequential Irinotecan + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients" @default.
• W2019416118 cites W1928747779 @default.
• W2019416118 cites W1965809073 @default.
• W2019416118 cites W1973824708 @default.
• W2019416118 cites W2037756952 @default.
• W2019416118 cites W2065064849 @default.
• W2019416118 cites W2085705101 @default.
• W2019416118 cites W2100471896 @default.
• W2019416118 cites W2102172908 @default.
• W2019416118 cites W2112759697 @default.
• W2019416118 cites W2119534563 @default.
• W2019416118 cites W2132545630 @default.
• W2019416118 cites W2134617967 @default.
• W2019416118 cites W2143743735 @default.
• W2019416118 cites W2157769714 @default.
• W2019416118 cites W2162731664 @default.
• W2019416118 cites W2165741055 @default.
• W2019416118 cites W2332894026 @default.
• W2019416118 doi "https://doi.org/10.1159/000339541" @default.
• W2019416118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22777333" @default.
• W2019416118 hasPublicationYear "2012" @default.
• W2019416118 type Work @default.
• W2019416118 sameAs 2019416118 @default.
• W2019416118 citedByCount "9" @default.
• W2019416118 countsByYear W20194161182013 @default.
• W2019416118 countsByYear W20194161182014 @default.
• W2019416118 countsByYear W20194161182015 @default.
• W2019416118 countsByYear W20194161182017 @default.
• W2019416118 countsByYear W20194161182018 @default.
• W2019416118 countsByYear W20194161182019 @default.
• W2019416118 countsByYear W20194161182022 @default.
• W2019416118 crossrefType "journal-article" @default.
• W2019416118 hasAuthorship W2019416118A5000941260 @default.
• W2019416118 hasAuthorship W2019416118A5000947818 @default.
• W2019416118 hasAuthorship W2019416118A5013149772 @default.
• W2019416118 hasAuthorship W2019416118A5015096398 @default.
• W2019416118 hasAuthorship W2019416118A5023481395 @default.
• W2019416118 hasAuthorship W2019416118A5040998619 @default.
• W2019416118 hasAuthorship W2019416118A5044498041 @default.
• W2019416118 hasAuthorship W2019416118A5047792722 @default.
• W2019416118 hasAuthorship W2019416118A5047801629 @default.
• W2019416118 hasAuthorship W2019416118A5052439214 @default.
• W2019416118 hasAuthorship W2019416118A5054084673 @default.
• W2019416118 hasAuthorship W2019416118A5061614047 @default.
• W2019416118 hasAuthorship W2019416118A5064504927 @default.
• W2019416118 hasAuthorship W2019416118A5069433827 @default.
• W2019416118 hasAuthorship W2019416118A5071947905 @default.
• W2019416118 hasAuthorship W2019416118A5073041790 @default.
• W2019416118 hasConcept C121608353 @default.
• W2019416118 hasConcept C126322002 @default.
• W2019416118 hasConcept C141071460 @default.
• W2019416118 hasConcept C143998085 @default.
• W2019416118 hasConcept C168563851 @default.
• W2019416118 hasConcept C203092338 @default.
• W2019416118 hasConcept C2776694085 @default.
• W2019416118 hasConcept C2777802072 @default.
• W2019416118 hasConcept C2780259306 @default.
• W2019416118 hasConcept C526805850 @default.
• W2019416118 hasConcept C71924100 @default.
• W2019416118 hasConcept C90924648 @default.
• W2019416118 hasConceptScore W2019416118C121608353 @default.
• W2019416118 hasConceptScore W2019416118C126322002 @default.
• W2019416118 hasConceptScore W2019416118C141071460 @default.
• W2019416118 hasConceptScore W2019416118C143998085 @default.
• W2019416118 hasConceptScore W2019416118C168563851 @default.
• W2019416118 hasConceptScore W2019416118C203092338 @default.
• W2019416118 hasConceptScore W2019416118C2776694085 @default.
• W2019416118 hasConceptScore W2019416118C2777802072 @default.
• W2019416118 hasConceptScore W2019416118C2780259306 @default.
• W2019416118 hasConceptScore W2019416118C526805850 @default.
• W2019416118 hasConceptScore W2019416118C71924100 @default.
• W2019416118 hasConceptScore W2019416118C90924648 @default.
• W2019416118 hasIssue "2" @default.
• W2019416118 hasLocation W20194161181 @default.
• W2019416118 hasLocation W20194161182 @default.
• W2019416118 hasOpenAccess W2019416118 @default.
• W2019416118 hasPrimaryLocation W20194161181 @default.
• W2019416118 hasRelatedWork W1993235655 @default.

• next